thrombosis

FFR to guide treatment of secondary vessel on bifurcations

Original title:&nbsp;Randomized Comparison of FFR-Guided and Angiography-Guided Provisional Stenting of True Coronary Bifurcation Lesions The DKCRUSH-VI (Double Kissing Crush Versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions VI) Trial.&nbsp;Reference:&nbsp;Shao-Liang Chen et al. J Am Coll Cardiol Intv. 2015. Online before print. Angiography for guiding the need to implant a stent in the side<a href="https://solaci.org/en/2015/04/22/ffr-to-guide-treatment-of-secondary-vessel-on-bifurcations/" title="Read more" >...</a>

Risks and benefits of extending dual antiplatelet therapy in patients with and without MI

Original title:&nbsp;Benefits and Risks of Extended Duration Dual Antiplatelet Therapy after PCI in Patients With and Without Acute Myocardial Infarction. The DAPT Study.&nbsp;Reference:&nbsp;Robert W. Yeh et al. J Am Coll Cardiol. 2015, online before print. The risks and benefits of prolonged antiplatelet therapy after PCI could be different in patients presenting with AMI compared to<a href="https://solaci.org/en/2015/04/21/risks-and-benefits-of-extending-dual-antiplatelet-therapy-in-patients-with-and-without-mi/" title="Read more" >...</a>

Duration of double antiaggregation therapy in patients with oral anticoagulation

Original title:&nbsp;Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent ImplantationThe ISAR-TRIPLE Trial.&nbsp;Reference:&nbsp;Katrin A. Fiedler et al. J Am Coll Cardiol. 2015;65(16):1619-1629. Patients with oral anticoagulation indication after drug eluting stenting require aspirin and clopidogrel; however, the triple scheme has high bleeding risk and optimal duration is yet to be determined. The<a href="https://solaci.org/en/2015/04/20/duration-of-double-antiaggregation-therapy-in-patients-with-oral-anticoagulation/" title="Read more" >...</a>

Is the 2nd generation DES an alternative to surgery in multivessel coronary disease?

The benefits of 2nd generation drug-eluting stents (DES) are being compared with Coronary artery bypass graft surgery (CABG), looking to achieve a safe, effective, less invasive and as complete as possible revascularization. As background of SYNTAX, the stent thrombosis (ST) with Taxus, reached 25% of the events in the group of intervention (PCI), so that<a href="https://solaci.org/en/2015/04/07/is-the-2nd-generation-des-an-alternative-to-surgery-in-multivessel-coronary-disease/" title="Read more" >...</a>

Bioresorbable vascular scaffold vs. the best-in-class DES

Original title:&nbsp;Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.&nbsp;Referencia:&nbsp;Puricel S. et al. J Am Coll Cardiol. 2015 Mar 3;65(8):791-801. The everolimus eluting bioresorbable scaffold (BVS) is effective at treating simple lesions in stable patients but it has yet to be assessed against the best-in-class DES. This study compared BVS performance against<a href="https://solaci.org/en/2015/04/01/bioresorbable-vascular-scaffold-vs-the-best-in-class-des/" title="Read more" >...</a>

Paclitaxel coated balloon catheter vs. DES for DES instent restenosis

Original title:&nbsp;Paclitaxel &ndash; coated balloon catheter compared with drug- eluting stent for drug-eluting stent restenosis in routine clinical practice.&nbsp;Reference:&nbsp;SeijiHabara et al.EuroIntervention 2015; 10-online publish-ahead-of-printFebruary 2015. The paclitaxel coated balloon catheter (PCB) is not inferior to DES for the treatment of instent restenosis (IRS). The aim of this study is to compare the efficacy of the<a href="https://solaci.org/en/2015/03/12/paclitaxel-coated-balloon-catheter-vs-des-for-des-instent-restenosis/" title="Read more" >...</a>

Double Anti platelet aggregation would be sufficient for six months after angioplasty in patients with stable coronary disease NSTSEACS.

Original title:&nbsp;6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug.&nbsp;Reference:&nbsp;Eluting Stents in Patients Nonresistant to Aspirin The Randomized, Multicenter ITALIC Trial. &nbsp;JACC.VOL. 65, NO. 8, 2015 Current recommendations on dual antiplatelet therapy (DAPT) are under review, particularly in acute coronary events due largely to the advent of second-generation stents. This work studied the hypothesis<a href="https://solaci.org/en/2015/03/10/double-anti-platelet-aggregation-would-be-sufficient-for-six-months-after-angioplasty-in-patients-with-stable-coronary-disease-nstseacs/" title="Read more" >...</a>

Zotarolimus eluting stent with one month of dual antiplatelet therapy

Original title:&nbsp;Zotarolimus-Eluting Versus Bare-Metal Stents in Uncertain Drug-Eluting Stent Candidates.&nbsp;Reference:&nbsp;Marco Valgimigli et al. J Am Coll Cardiol. 2015;65(8):805-815. The use of drug eluting stents (DES) in patients at high risk of bleeding or thrombosis has not been studied prospectively. Data on patients at high risk of bleeding and low restenosis are limited. This study compared<a href="https://solaci.org/en/2015/02/25/zotarolimus-eluting-stent-with-one-month-of-dual-antiplatelet-therapy/" title="Read more" >...</a>

Pretreatment with clopidogrel only for ST elevation AMI patients

Original title:&nbsp;Prognostic impact of clopidogrel pretreatment in patients with acute coronary syndrome managed invasively.&nbsp;Reference:&nbsp;Almendro-Delia M et al. Am J Cardiol. 2015; Epub ahead of print. This study analyzed the ARIAM data including 9621 AMI patients diagnosed with coronary angiography receiving clopidogrel in 49 center between 2002 and 2012. Most patients had STEMI (63%), and most<a href="https://solaci.org/en/2015/02/09/pretreatment-with-clopidogrel-only-for-st-elevation-ami-patients/" title="Read more" >...</a>

Net clinical benefit of bivalirudin in STEMI patients

Original title:&nbsp;Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: Pooled Patient-Level Analysis From the HORIZONS-AMI and EUROMAX Trials.&nbsp;Reference:&nbsp;Stone GW et al. J Am CollCardiol. 2015 Jan 6;65(1):27-38. The HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) that included 3602 STEMI patients undergoing<a href="https://solaci.org/en/2015/01/29/net-clinical-benefit-of-bivalirudin-in-stemi-patients/" title="Read more" >...</a>

Top